SAN ANTONIO, July 30, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the issuance of a United States patent entitled "Methods and compositions for the detection of cancer". The patent US 8,772,226 B2 was issued July 8, 2014.

IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that it has received combined clearances from the U.S. Food and Drug Administration (FDA) that will enable IBA to market-launch the Proton Therapy specific Cone Beam Computed Tomography (CBCT) solution.

The University of California San Francisco is creating a magical new world of woodland forests and cable cars in a family friendly molecular imaging and radiology suite, reports SF Gate. 

Bruker Corporation of Billerica, Mass., has announced that the provider of instrumentation for biomedical research has acquired Vutara Incorporated, producers of high-speed and resolution 3D fluorescence microscopy.

Lasting memories of trauma and aversion can be passed on from mother-to-baby in a kind of biochemical generational stamp, researchers from the University of Michigan announced yesterday.

Based on its recent analysis of the breast imaging systems market, Frost and Sullivan recognizes Gamma Medica with the 2014 Global Frost and Sullivan Award for Product Leadership.

A handful of new genetic variants point to Parkinson’s disease, the National Institutes of Health (NIH) announced yesterday. The six previously unreported risk factors will contribute to researchers’ understanding as they work to develop better treatments for the neurodegenerative disease.

The industry for Alzheimer’s drug treatments is expected to grow from modest beginnings to big business in the next decade, according to a June report by Decision Resources Group.